We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


ProNAi and Novosom Announce Collaboration to Deliver DNAi®-Based Cancer Therapeutics

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

ProNAi Therapeutics, Inc. has announced collaboration with Novosom AG to enable successful delivery of DNAi®-based cancer therapeutics.

Under the terms of the collaboration, ProNAi will license Novosom’s SMARTICLES® liposome technology for use in all human disease targeted by ProNAi’s PNT100 drug candidate. The agreement comprises an upfront payment, milestone payments and royalties, composed of a mixture of cash and equity. ProNAi will also retain an option for four additional DNAi® targets.

Dr. Richard D. Gill, President and CEO of ProNAi, said, “Team ProNAi is very much looking forward to realizing the results of our collaboration with Novosom in this groundbreaking endeavor, as we bring the drug product PNT2258 to IND submission. The successful delivery of nucleic acid-based drugs has been the ‘holy grail’ of the industry for many years, and we are confident that our combined approach will yield promising outcomes.”

Gill continued, “With this partnership, we have developed a GMP-enabling oligo delivery method that allows ProNAi to submit an IND, and we expect more significant milestones to be met in the near future.”

Elias Papatheodorou, CEO of Novosom, said, “Novosom’s technology has been in the forefront of providing a safer, more efficient delivery method available for in vivo delivery of nucleotides to targeted cells. We are encouraged by the potential our partnership with ProNAi holds in developing a new class of effective DNA-based drugs.”